EGF816
Total Payments
$1.0M
Transactions
24
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $51,924 | 6 | 0 |
| 2019 | $176,758 | 5 | 0 |
| 2018 | $276,083 | 7 | 0 |
| 2017 | $513,450 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 24 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE L AND OR LL MULTICENTER OPEN LABEL STUDY OF EGFRMUT TKI EGF816 ADMINISTERED ORALLY IN ADULT PATIENTS WITH EGFRMUT SOLID MALIGNANCIES | Novartis Pharmaceuticals Corporation | $675,963 | 0 |
| EGF816 PLUS GEFITINIB FOR TKI NAIVE EGFR MUTANT NSCLC | Novartis Pharmaceuticals Corporation | $157,670 | 0 |
| A PHASE II MULTICENTER OPEN LABEL STUDY OF EGF816 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH EGFR MUTATED NON SMALL CELL LUNG CANCER AND OF INC280 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH CMET POSITIVE NON SMALL CELL LUNG CANCER | NOVARTIS PHARMACEUTICALS CORPORATION | $97,792 | 0 |
| A PHASE II MULTICENTER OPEN LABEL STUDY OF EGF816 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH EGFR MUTATED NON SMALL CELL LUNG CANCER AND OF INC280 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH CMET POSITIVE NON SMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $65,965 | 0 |
| A PHASE IB OPEN LABEL MULTI CENTER STUDY TO CHARACTERIZE THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF EGF816 IN COMBINATION WITH SELECTED TARGETED AGENTS IN EGFR MUTANT NSCLC | Novartis Pharmaceuticals Corporation | $20,825 | 0 |
Top Doctors Receiving Payments for EGF816
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlotte, NC | $1.0M | 24 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $920,422
- NOVARTIS PHARMACEUTICALS CORPORATION $97,792
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 0
- Transactions 24
About EGF816
EGF816 is a drug associated with $1.0M in payments to 0 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $51,924 was paid across 6 transactions to 0 doctors.
The most common payment nature for EGF816 is "Unspecified" ($1.0M, 100.0% of total).
EGF816 is associated with 5 research studies, including "A PHASE L AND OR LL MULTICENTER OPEN LABEL STUDY OF EGFRMUT TKI EGF816 ADMINISTERED ORALLY IN ADULT PATIENTS WITH EGFRMUT SOLID MALIGNANCIES" ($675,963).